Axovant races to PhIII dementia study as nelotanserin clears an early hurdle, but questions linger
Axovant says that its drug nelotanserin has cleared an early hurdle in a Phase II study for Lewy body dementia, triggering a decision to expand the mid-stage trial and hitting the green light for a Phase III to get started later this year. But investors are likely to question a stumble on key secondary goals.
A snapshot of results for the first tiny group of 11 patients concluded that they were demonstrating statistically significant responses to the drug on the primary endpoint. These patients included people suffering from Parkinson’s as well as Lewy body dementia. They were recruited after suffering from frequent visual hallucinations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
